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Sir,
We read the letter from Quinn et al with interest and are glad to
have an opportunity to acknowledge the cooperation received
from the staff at the ONS throughout our study. The ONS team
made considerable efforts to provide comprehensive reporting of
ovarian cancer cases. Our report was not intended to be a criticism
of the important work performed by the NHSCR.
We reported our comparison of ‘direct’ and NHSCR follow up
for ovarian cancer in order to provide information for the design of
future research studies. Although the two methods of follow up are
complementary, direct follow up identified more cases of ovarian
cancer and identified them in a shorter period of time than was
possible via the NHSCR. Researchers need to be aware of the
issues of incomplete registration and the delay in notification
through the NHSCR and consider the option of using an additional
method of follow up. These issues have major implications for the
design of clinical trials and in this context we hope that the data
provided by our study is of some value.
Quinn et al highlighted the limitations of ‘follow-up’ compared to
‘flagging’ studies via the NHSCR. Whilst these points are entirely
valid they do not explain the eleven cases of ovarian cancer not
identified by the NHSCR in our study. First, follow up was carried
out by the NHSCR in 1997–98, a time point more than five years
after diagnosis of the ovarian cancer cases in our study. Second,
repeated searches were performed by the NHSCR for the eleven
cases both manually and by computer. Although the data originally
supplied to the NHSCR was incomplete for some study participants,
complete data for the relevant eleven cases was resubmitted for
additional searches once the discrepancy was identified. It is
possible that flagging would eventually identify these cases but a
delay of more than five years from study completion to analysis has
major implications for a clinical trial. As noted by Quinn et al a total
of four cases of ovarian cancer reported by the NHSCR were not
identified by direct follow-up. However, the study was limited to
cases diagnosed between 1986 and 1993 because this allowed a 5
year period for data collection by the NHSCR and was the period of
direct follow. Two cases of ovarian cancer identified by the NHSCR
but diagnosed after 1993 were not therefore reported in our paper.
The same applies to three other cases of ovarian cancer diagnosed
after 1993 but not identified by the NHSCR.
It seems sensible for researchers currently designing clinical
studies requiring long-term follow-up to consider using direct
follow up as well as flagging with the NHSCR. Direct follow up is
a rapid and reliable means of identifying cancer cases which
complements information provided by the NHSCR. Major efforts
and numerous changes are being made in the cancer registration
system which are improving the research value of this key
resource. We strongly support investment in cancer registration
and appreciate the efforts being made by staff in the regional
cancer registries and at the ONS. Hopefully in the future the use of
direct follow up in clinical trials will not be necessary!
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